Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 23

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

283

Figures (1-2)

Tables (1-2)

Sum=353

Publishing Process of This Article

Item

Count

Browse

Download

Sum=34

Jun 21, 2024 (publication date) through Jun 29, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 21, 2024; 30(23): 2964-2980
Published online Jun 21, 2024. doi: 10.3748/wjg.v30.i23.2964

Table 2 The influence of the type of treatment on the comparison of gut microbiota

Bacteria levels	GLP-1 RAs	GLP-1/GLP-2 RA	Roux-en-Y gastric bypass surgery
Increase	Bifidobacteriaceae	Bifidobacteriaceae	Bacteroidetes
	Actinobacteria	Prevotellaceae	Actinobacteria
	Akkermansiaceae	Lactobacillaceae	Proteobacteria
		Akkermansiaceae	Akkermansiaceae
Decrease	Firmicutes	Firmicutes	Firmicutes
	Oscillospiraceae		Oscillospiraceae
	Bacteroidetes
Microbiota diversity	Increase	Increase	Increase

GLP-1 RAs: Glucagon-like peptide-1 receptor agonists; GLP-1/GLP-2 RA: Dual glucagon-like peptide-1 and glucagon-like peptide-2 receptor agonist.

Citation: Rochoń J, Kalinowski P, Szymanek-Majchrzak K, Grąt M. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2024; 30(23): 2964-2980
URL: https://www.wjgnet.com/1007-9327/full/v30/i23/2964.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i23.2964